Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2012

Open Access 01-12-2012 | Letter to the Editor

Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia

Authors: Ning Li, Yongping Song, Jian Zhou, Baijun Fang

Published in: Journal of Hematology & Oncology | Issue 1/2012

Login to get access

Abstract

We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. If necessary, a second course was performed after an interval of one week. All patients achieved clinically significant responses to ATO. The overall complete response rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively. So treatment with ATO may be a feasible approach in patients with refractory SAA.
Appendix
Available only for authorised users
Literature
1.
Rosenfeld S, Follmann D, Nunez O, Young NS: Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003, 289: 1130-1135. 10.1001/jama.289.9.1130.CrossRefPubMed
2.
Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ: Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature. 2009, 460: 259-263. 10.1038/nature08099.PubMedCentralCrossRefPubMed
3.
Corre J, Barreau C, Cousin B, Chavoin JP, Caton D, Fournial G, Penicaud L, Casteilla L, Laharrague P: Human subcutaneous adipose cells support complete differentiation but not self-renewal of hematopoietic progenitors. J Cell Physiol. 2006, 208: 282-288. 10.1002/jcp.20655.CrossRefPubMed
4.
Nishikawa M, Ozawa K, Tojo A, Yoshikubo T, Okano A, Tani K, Ikebuchi K, Nakauchi H, Asano S: Changes in hematopoiesis-supporting ability of C3H10T1/2 mouse embryo fibroblasts during differentiation. Blood. 1993, 81: 1184-1192.PubMed
5.
Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT: Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003, 425: 841-846. 10.1038/nature02040.CrossRefPubMed
6.
Tavassoli M, Maniatis A, Crosby WH: Induction of sustained hemopoiesis in fatty marrow. Blood. 1974, 43: 33-38.PubMed
7.
Nuttall ME, Gimble JM: Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol. 2004, 4: 290-294. 10.1016/j.coph.2004.03.002.CrossRefPubMed
8.
Cheng H, Qiu L, Zhang H, Cheng M, Li W, Zhao X, Liu K, Lei L, Ma J: Arsenic trioxide promotes senescence and regulates the balance of adipogenic and osteogenic differentiation in human mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai). 2011, 43: 204-209. 10.1093/abbs/gmq130.CrossRef
9.
Song Y, Li N, Liu Y, Fang B: Improved outcome of adults with aplastic anemia treated with arsenic trioxide plus cyclosporine. Br J Haematol. In press
Metadata
Title
Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
Authors
Ning Li
Yongping Song
Jian Zhou
Baijun Fang
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-5-61

Other articles of this Issue 1/2012

Journal of Hematology & Oncology 1/2012 Go to the issue

Review

Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies

Letter to the Editor

SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia

Review

Recent updates on the role of microRNAs in prostate cancer

Research

Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome

Research

Correlation of SRSF1 and PRMT1 expression with clinical status of pediatric acute lymphoblastic leukemia

Rapid communication

Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits